Alkermes plc, a company listed on Nasdaq (ALKS), has announced that it will start accepting applications for its annual Alkermes Pathways Research Awards® program from Friday, Sept. 15, 2023. This marks the sixth year of this competitive grant program, which aims to support emerging researchers in their efforts to enhance our knowledge of diseases in the neuroscience field. The program will provide grants to early-career investigators who have shown dedication to advancing research in schizophrenia or bipolar disorder. The application period will last until Nov. 30, 2023.
Craig Hopkinson, M.D., Chief Medical Officer and Executive Vice President of Research and Development at Alkermes, stated that their commitment to great science is reflected in their support for these innovative research projects. He expressed pride in the Pathways program’s impact so far in supporting early-career researchers who are committed to improving the lives of people with complex diseases like schizophrenia and bipolar disorder.
The 6th annual Alkermes Pathways Research Awards program will provide grants of up to $100,000 per project. Eligible early-career investigators include M.D.s, Ph.D.s, or equivalent, who are within five years of their initial academic appointment or are current post-doctoral fellows, and who are affiliated with a medical or research institution within the United States. Applications will be reviewed by an independent committee of specialists in psychiatry, neurobiology, pharmacology, and behavioral science from academic research centers.
Since its inception in 2018, the Pathways program has provided approximately $2.3 million in funding to 23 researchers across the United States. These award recipients have conducted significant mentor-supported research to contribute to advancements in the field of neuroscience.
To know more on the Alkermes Pathways Research Awards program, click here.
Craig Hopkinson, M.D., Chief Medical Officer and Executive Vice President of Research and Development at Alkermes, stated that their commitment to great science is reflected in their support for these innovative research projects. He expressed pride in the Pathways program’s impact so far in supporting early-career researchers who are committed to improving the lives of people with complex diseases like schizophrenia and bipolar disorder.
The 6th annual Alkermes Pathways Research Awards program will provide grants of up to $100,000 per project. Eligible early-career investigators include M.D.s, Ph.D.s, or equivalent, who are within five years of their initial academic appointment or are current post-doctoral fellows, and who are affiliated with a medical or research institution within the United States. Applications will be reviewed by an independent committee of specialists in psychiatry, neurobiology, pharmacology, and behavioral science from academic research centers.
Since its inception in 2018, the Pathways program has provided approximately $2.3 million in funding to 23 researchers across the United States. These award recipients have conducted significant mentor-supported research to contribute to advancements in the field of neuroscience.
To know more on the Alkermes Pathways Research Awards program, click here.